LymphedemaV1, PubMed, Curation, bibRecord, 000B76

Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.

Identifieur interne : 000B76 ( PubMed/Curation ); précédent : 000B75; suivant : 000B77

Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.

Auteurs : Edward K. Thomsen [Papouasie-Nouvelle-Guinée] ; Nelly Sanuku [Papouasie-Nouvelle-Guinée] ; Manasseh Baea [Papouasie-Nouvelle-Guinée] ; Samson Satofan [Papouasie-Nouvelle-Guinée] ; Elit Maki [Papouasie-Nouvelle-Guinée] ; Bart Lombore [Papouasie-Nouvelle-Guinée] ; Mark S. Schmidt [États-Unis] ; Peter M. Siba [Papouasie-Nouvelle-Guinée] ; Gary J. Weil [États-Unis] ; James W. Kazura [États-Unis] ; Lawrence L. Fleckenstein [États-Unis] ; Christopher L. King [États-Unis]

Source :

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [ 1537-6591 ] ; 2016.

RBID : pubmed:26486704

Descripteurs français

KwdFr :
- Adulte, Adulte d'âge moyen, Albendazole (administration et posologie), Albendazole (effets indésirables), Albendazole (pharmacocinétique), Animaux, Diéthylcarbamazine (administration et posologie), Diéthylcarbamazine (effets indésirables), Diéthylcarbamazine (pharmacocinétique), Effets secondaires indésirables des médicaments (anatomopathologie), Femelle, Filaricides (administration et posologie), Filaricides (effets indésirables), Filaricides (pharmacocinétique), Filariose lymphatique (traitement médicamenteux), Humains, Ivermectine (administration et posologie), Ivermectine (effets indésirables), Ivermectine (pharmacocinétique), Jeune adulte, Mâle, Méthode en simple aveugle, Papouasie - Nouvelle-Guinée, Parasitémie (traitement médicamenteux), Projets pilotes, Résultat thérapeutique, Sérum (), Wuchereria bancrofti (isolement et purification).
MESH :
- administration et posologie : Albendazole, Diéthylcarbamazine, Filaricides, Ivermectine.
- anatomopathologie : Effets secondaires indésirables des médicaments.
- effets indésirables : Albendazole, Diéthylcarbamazine, Filaricides, Ivermectine.
- isolement et purification : Wuchereria bancrofti.
- pharmacocinétique : Albendazole, Diéthylcarbamazine, Filaricides, Ivermectine.
- traitement médicamenteux : Filariose lymphatique, Parasitémie.
- Adulte, Adulte d'âge moyen, Animaux, Femelle, Humains, Jeune adulte, Mâle, Méthode en simple aveugle, Papouasie - Nouvelle-Guinée, Projets pilotes, Résultat thérapeutique, Sérum.

English descriptors

KwdEn :
- Adult, Albendazole (administration & dosage), Albendazole (adverse effects), Albendazole (pharmacokinetics), Animals, Diethylcarbamazine (administration & dosage), Diethylcarbamazine (adverse effects), Diethylcarbamazine (pharmacokinetics), Drug-Related Side Effects and Adverse Reactions (pathology), Elephantiasis, Filarial (drug therapy), Female, Filaricides (administration & dosage), Filaricides (adverse effects), Filaricides (pharmacokinetics), Humans, Ivermectin (administration & dosage), Ivermectin (adverse effects), Ivermectin (pharmacokinetics), Male, Middle Aged, Papua New Guinea, Parasitemia (drug therapy), Pilot Projects, Serum (chemistry), Single-Blind Method, Treatment Outcome, Wuchereria bancrofti (isolation & purification), Young Adult.
MESH :
- chemical , administration & dosage : Albendazole, Diethylcarbamazine, Filaricides, Ivermectin.
- chemical , adverse effects : Albendazole, Diethylcarbamazine, Filaricides, Ivermectin.
- chemical , pharmacokinetics : Albendazole, Diethylcarbamazine, Filaricides, Ivermectin.
- chemistry : Serum.
- drug therapy : Elephantiasis, Filarial, Parasitemia.
- isolation & purification : Wuchereria bancrofti.
- pathology : Drug-Related Side Effects and Adverse Reactions.
- Adult, Animals, Female, Humans, Male, Middle Aged, Papua New Guinea, Pilot Projects, Single-Blind Method, Treatment Outcome, Young Adult.

Abstract

Available treatments for lymphatic filariasis (LF) are limited in their longterm clearance of microfilaria from the blood. The safety and efficacy of a single-dose triple-drug therapy of the antifilarial drugs diethylcarbamazine (DEC), ivermectin (IVM), and albendazole (ALB) for LF are unknown.

DOI: 10.1093/cid/civ882
PubMed: 26486704

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000B76

Links to Exploration step

pubmed:26486704

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.</title>
<author><name sortKey="Thomsen, Edward K" sort="Thomsen, Edward K" uniqKey="Thomsen E" first="Edward K" last="Thomsen">Edward K. Thomsen</name>
<affiliation wicri:level="1"><nlm:affiliation>Papua New Guinea Institute of Medical Research, Papua New Guinea.</nlm:affiliation>
<country xml:lang="fr">Papouasie-Nouvelle-Guinée</country>
<wicri:regionArea>Papua New Guinea Institute of Medical Research</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Sanuku, Nelly" sort="Sanuku, Nelly" uniqKey="Sanuku N" first="Nelly" last="Sanuku">Nelly Sanuku</name>
<affiliation wicri:level="1"><nlm:affiliation>Papua New Guinea Institute of Medical Research, Papua New Guinea.</nlm:affiliation>
<country xml:lang="fr">Papouasie-Nouvelle-Guinée</country>
<wicri:regionArea>Papua New Guinea Institute of Medical Research</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Baea, Manasseh" sort="Baea, Manasseh" uniqKey="Baea M" first="Manasseh" last="Baea">Manasseh Baea</name>
<affiliation wicri:level="1"><nlm:affiliation>Papua New Guinea Institute of Medical Research, Papua New Guinea.</nlm:affiliation>
<country xml:lang="fr">Papouasie-Nouvelle-Guinée</country>
<wicri:regionArea>Papua New Guinea Institute of Medical Research</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Satofan, Samson" sort="Satofan, Samson" uniqKey="Satofan S" first="Samson" last="Satofan">Samson Satofan</name>
<affiliation wicri:level="1"><nlm:affiliation>Papua New Guinea Institute of Medical Research, Papua New Guinea.</nlm:affiliation>
<country xml:lang="fr">Papouasie-Nouvelle-Guinée</country>
<wicri:regionArea>Papua New Guinea Institute of Medical Research</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Maki, Elit" sort="Maki, Elit" uniqKey="Maki E" first="Elit" last="Maki">Elit Maki</name>
<affiliation wicri:level="1"><nlm:affiliation>Papua New Guinea Institute of Medical Research, Papua New Guinea.</nlm:affiliation>
<country xml:lang="fr">Papouasie-Nouvelle-Guinée</country>
<wicri:regionArea>Papua New Guinea Institute of Medical Research</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lombore, Bart" sort="Lombore, Bart" uniqKey="Lombore B" first="Bart" last="Lombore">Bart Lombore</name>
<affiliation wicri:level="1"><nlm:affiliation>Papua New Guinea Institute of Medical Research, Papua New Guinea.</nlm:affiliation>
<country xml:lang="fr">Papouasie-Nouvelle-Guinée</country>
<wicri:regionArea>Papua New Guinea Institute of Medical Research</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Schmidt, Mark S" sort="Schmidt, Mark S" uniqKey="Schmidt M" first="Mark S" last="Schmidt">Mark S. Schmidt</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pharmaceutical Sciences & Experimental Therapeutics, University of Iowa, Iowa City.</nlm:affiliation>
<orgName type="university">Université de l'Iowa</orgName>
<country>États-Unis</country>
<placeName><settlement type="city">Iowa City</settlement>
<region type="state">Iowa</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Siba, Peter M" sort="Siba, Peter M" uniqKey="Siba P" first="Peter M" last="Siba">Peter M. Siba</name>
<affiliation wicri:level="1"><nlm:affiliation>Papua New Guinea Institute of Medical Research, Papua New Guinea.</nlm:affiliation>
<country xml:lang="fr">Papouasie-Nouvelle-Guinée</country>
<wicri:regionArea>Papua New Guinea Institute of Medical Research</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Weil, Gary J" sort="Weil, Gary J" uniqKey="Weil G" first="Gary J" last="Weil">Gary J. Weil</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Infectious Diseases Division, Washington University School of Medicine, St. Louis, Missouri.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Missouri (État)</region>
</placeName>
<wicri:cityArea>Department of Medicine, Infectious Diseases Division, Washington University School of Medicine, St. Louis</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Kazura, James W" sort="Kazura, James W" uniqKey="Kazura J" first="James W" last="Kazura">James W. Kazura</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Fleckenstein, Lawrence L" sort="Fleckenstein, Lawrence L" uniqKey="Fleckenstein L" first="Lawrence L" last="Fleckenstein">Lawrence L. Fleckenstein</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pharmaceutical Sciences & Experimental Therapeutics, University of Iowa, Iowa City.</nlm:affiliation>
<orgName type="university">Université de l'Iowa</orgName>
<country>États-Unis</country>
<placeName><settlement type="city">Iowa City</settlement>
<region type="state">Iowa</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="King, Christopher L" sort="King, Christopher L" uniqKey="King C" first="Christopher L" last="King">Christopher L. King</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:26486704</idno>
<idno type="pmid">26486704</idno>
<idno type="doi">10.1093/cid/civ882</idno>
<idno type="wicri:Area/PubMed/Corpus">000B76</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B76</idno>
<idno type="wicri:Area/PubMed/Curation">000B76</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B76</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.</title>
<author><name sortKey="Thomsen, Edward K" sort="Thomsen, Edward K" uniqKey="Thomsen E" first="Edward K" last="Thomsen">Edward K. Thomsen</name>
<affiliation wicri:level="1"><nlm:affiliation>Papua New Guinea Institute of Medical Research, Papua New Guinea.</nlm:affiliation>
<country xml:lang="fr">Papouasie-Nouvelle-Guinée</country>
<wicri:regionArea>Papua New Guinea Institute of Medical Research</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Sanuku, Nelly" sort="Sanuku, Nelly" uniqKey="Sanuku N" first="Nelly" last="Sanuku">Nelly Sanuku</name>
<affiliation wicri:level="1"><nlm:affiliation>Papua New Guinea Institute of Medical Research, Papua New Guinea.</nlm:affiliation>
<country xml:lang="fr">Papouasie-Nouvelle-Guinée</country>
<wicri:regionArea>Papua New Guinea Institute of Medical Research</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Baea, Manasseh" sort="Baea, Manasseh" uniqKey="Baea M" first="Manasseh" last="Baea">Manasseh Baea</name>
<affiliation wicri:level="1"><nlm:affiliation>Papua New Guinea Institute of Medical Research, Papua New Guinea.</nlm:affiliation>
<country xml:lang="fr">Papouasie-Nouvelle-Guinée</country>
<wicri:regionArea>Papua New Guinea Institute of Medical Research</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Satofan, Samson" sort="Satofan, Samson" uniqKey="Satofan S" first="Samson" last="Satofan">Samson Satofan</name>
<affiliation wicri:level="1"><nlm:affiliation>Papua New Guinea Institute of Medical Research, Papua New Guinea.</nlm:affiliation>
<country xml:lang="fr">Papouasie-Nouvelle-Guinée</country>
<wicri:regionArea>Papua New Guinea Institute of Medical Research</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Maki, Elit" sort="Maki, Elit" uniqKey="Maki E" first="Elit" last="Maki">Elit Maki</name>
<affiliation wicri:level="1"><nlm:affiliation>Papua New Guinea Institute of Medical Research, Papua New Guinea.</nlm:affiliation>
<country xml:lang="fr">Papouasie-Nouvelle-Guinée</country>
<wicri:regionArea>Papua New Guinea Institute of Medical Research</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lombore, Bart" sort="Lombore, Bart" uniqKey="Lombore B" first="Bart" last="Lombore">Bart Lombore</name>
<affiliation wicri:level="1"><nlm:affiliation>Papua New Guinea Institute of Medical Research, Papua New Guinea.</nlm:affiliation>
<country xml:lang="fr">Papouasie-Nouvelle-Guinée</country>
<wicri:regionArea>Papua New Guinea Institute of Medical Research</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Schmidt, Mark S" sort="Schmidt, Mark S" uniqKey="Schmidt M" first="Mark S" last="Schmidt">Mark S. Schmidt</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pharmaceutical Sciences & Experimental Therapeutics, University of Iowa, Iowa City.</nlm:affiliation>
<orgName type="university">Université de l'Iowa</orgName>
<country>États-Unis</country>
<placeName><settlement type="city">Iowa City</settlement>
<region type="state">Iowa</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Siba, Peter M" sort="Siba, Peter M" uniqKey="Siba P" first="Peter M" last="Siba">Peter M. Siba</name>
<affiliation wicri:level="1"><nlm:affiliation>Papua New Guinea Institute of Medical Research, Papua New Guinea.</nlm:affiliation>
<country xml:lang="fr">Papouasie-Nouvelle-Guinée</country>
<wicri:regionArea>Papua New Guinea Institute of Medical Research</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Weil, Gary J" sort="Weil, Gary J" uniqKey="Weil G" first="Gary J" last="Weil">Gary J. Weil</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Infectious Diseases Division, Washington University School of Medicine, St. Louis, Missouri.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Missouri (État)</region>
</placeName>
<wicri:cityArea>Department of Medicine, Infectious Diseases Division, Washington University School of Medicine, St. Louis</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Kazura, James W" sort="Kazura, James W" uniqKey="Kazura J" first="James W" last="Kazura">James W. Kazura</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Fleckenstein, Lawrence L" sort="Fleckenstein, Lawrence L" uniqKey="Fleckenstein L" first="Lawrence L" last="Fleckenstein">Lawrence L. Fleckenstein</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pharmaceutical Sciences & Experimental Therapeutics, University of Iowa, Iowa City.</nlm:affiliation>
<orgName type="university">Université de l'Iowa</orgName>
<country>États-Unis</country>
<placeName><settlement type="city">Iowa City</settlement>
<region type="state">Iowa</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="King, Christopher L" sort="King, Christopher L" uniqKey="King C" first="Christopher L" last="King">Christopher L. King</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</title>
<idno type="eISSN">1537-6591</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Albendazole (administration & dosage)</term>
<term>Albendazole (adverse effects)</term>
<term>Albendazole (pharmacokinetics)</term>
<term>Animals</term>
<term>Diethylcarbamazine (administration & dosage)</term>
<term>Diethylcarbamazine (adverse effects)</term>
<term>Diethylcarbamazine (pharmacokinetics)</term>
<term>Drug-Related Side Effects and Adverse Reactions (pathology)</term>
<term>Elephantiasis, Filarial (drug therapy)</term>
<term>Female</term>
<term>Filaricides (administration & dosage)</term>
<term>Filaricides (adverse effects)</term>
<term>Filaricides (pharmacokinetics)</term>
<term>Humans</term>
<term>Ivermectin (administration & dosage)</term>
<term>Ivermectin (adverse effects)</term>
<term>Ivermectin (pharmacokinetics)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Papua New Guinea</term>
<term>Parasitemia (drug therapy)</term>
<term>Pilot Projects</term>
<term>Serum (chemistry)</term>
<term>Single-Blind Method</term>
<term>Treatment Outcome</term>
<term>Wuchereria bancrofti (isolation & purification)</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Albendazole (administration et posologie)</term>
<term>Albendazole (effets indésirables)</term>
<term>Albendazole (pharmacocinétique)</term>
<term>Animaux</term>
<term>Diéthylcarbamazine (administration et posologie)</term>
<term>Diéthylcarbamazine (effets indésirables)</term>
<term>Diéthylcarbamazine (pharmacocinétique)</term>
<term>Effets secondaires indésirables des médicaments (anatomopathologie)</term>
<term>Femelle</term>
<term>Filaricides (administration et posologie)</term>
<term>Filaricides (effets indésirables)</term>
<term>Filaricides (pharmacocinétique)</term>
<term>Filariose lymphatique (traitement médicamenteux)</term>
<term>Humains</term>
<term>Ivermectine (administration et posologie)</term>
<term>Ivermectine (effets indésirables)</term>
<term>Ivermectine (pharmacocinétique)</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Méthode en simple aveugle</term>
<term>Papouasie - Nouvelle-Guinée</term>
<term>Parasitémie (traitement médicamenteux)</term>
<term>Projets pilotes</term>
<term>Résultat thérapeutique</term>
<term>Sérum ()</term>
<term>Wuchereria bancrofti (isolement et purification)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Albendazole</term>
<term>Diethylcarbamazine</term>
<term>Filaricides</term>
<term>Ivermectin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Albendazole</term>
<term>Diethylcarbamazine</term>
<term>Filaricides</term>
<term>Ivermectin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Albendazole</term>
<term>Diethylcarbamazine</term>
<term>Filaricides</term>
<term>Ivermectin</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Albendazole</term>
<term>Diéthylcarbamazine</term>
<term>Filaricides</term>
<term>Ivermectine</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Serum</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term>
<term>Parasitemia</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Albendazole</term>
<term>Diéthylcarbamazine</term>
<term>Filaricides</term>
<term>Ivermectine</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Wuchereria bancrofti</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Wuchereria bancrofti</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Albendazole</term>
<term>Diéthylcarbamazine</term>
<term>Filaricides</term>
<term>Ivermectine</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term>
<term>Parasitémie</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Animals</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Papua New Guinea</term>
<term>Pilot Projects</term>
<term>Single-Blind Method</term>
<term>Treatment Outcome</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Animaux</term>
<term>Femelle</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Méthode en simple aveugle</term>
<term>Papouasie - Nouvelle-Guinée</term>
<term>Projets pilotes</term>
<term>Résultat thérapeutique</term>
<term>Sérum</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Available treatments for lymphatic filariasis (LF) are limited in their longterm clearance of microfilaria from the blood. The safety and efficacy of a single-dose triple-drug therapy of the antifilarial drugs diethylcarbamazine (DEC), ivermectin (IVM), and albendazole (ALB) for LF are unknown.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26486704</PMID>
<DateCreated><Year>2016</Year>
<Month>01</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>10</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>05</Month>
<Day>12</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>62</Volume>
<Issue>3</Issue>
<PubDate><Year>2016</Year>
<Month>Feb</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title>
<ISOAbbreviation>Clin. Infect. Dis.</ISOAbbreviation>
</Journal>
<ArticleTitle>Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.</ArticleTitle>
<Pagination><MedlinePgn>334-341</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/civ882</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Available treatments for lymphatic filariasis (LF) are limited in their longterm clearance of microfilaria from the blood. The safety and efficacy of a single-dose triple-drug therapy of the antifilarial drugs diethylcarbamazine (DEC), ivermectin (IVM), and albendazole (ALB) for LF are unknown.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We performed a pilot study to test the efficacy, safety, and pharmacokinetics of single-dose DEC, IVM, and ALB in Wuchereria bancrofti-infected Papua New Guineans. Adults were randomized into 2 treatment arms, DEC 6 mg/kg + ALB 400 mg (N = 12) or DEC 6 mg/kg + ALB 400 mg + IVM 200 μg/kg (N = 12), and monitored for microfilaria, parasite antigenemia, adverse events (AEs), and serum drug levels.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Triple-drug therapy induced >2-log reductions in microfilaria levels at 36 and 168 hours after treatment compared with approximately 1-log reduction with 2 drugs. All 12 individuals who received 3 drugs were microfilaria negative 1 year after treatment, whereas 11 of 12 individuals in the 2-drug regimen were microfilaria positive. In 6 participants followed 2 years after treatment, those who received 3 drugs remained microfilaria negative. AEs, particularly fever, myalgias, pruritus, and proteinuria/hematuria, occurred in 83% vs 50% of those receiving triple-drug compared to 2-drug treatment respectively (P = .021); all resolved within 7 days after treatment. No serious AEs were observed in either group. There was no significant effect of IVM on DEC or ALB drug levels.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Triple-drug therapy is safe and more effective than DEC + ALB for Bancroftian filariasis and has the potential to accelerate elimination of lymphatic filariasis.</AbstractText>
<AbstractText Label="CLINICAL TRIALS REGISTRATION" NlmCategory="BACKGROUND">NCT01975441.</AbstractText>
<CopyrightInformation>© The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thomsen</LastName>
<ForeName>Edward K</ForeName>
<Initials>EK</Initials>
<AffiliationInfo><Affiliation>Papua New Guinea Institute of Medical Research, Papua New Guinea.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sanuku</LastName>
<ForeName>Nelly</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Papua New Guinea Institute of Medical Research, Papua New Guinea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Baea</LastName>
<ForeName>Manasseh</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Papua New Guinea Institute of Medical Research, Papua New Guinea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Satofan</LastName>
<ForeName>Samson</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Papua New Guinea Institute of Medical Research, Papua New Guinea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Maki</LastName>
<ForeName>Elit</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Papua New Guinea Institute of Medical Research, Papua New Guinea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lombore</LastName>
<ForeName>Bart</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Papua New Guinea Institute of Medical Research, Papua New Guinea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schmidt</LastName>
<ForeName>Mark S</ForeName>
<Initials>MS</Initials>
<AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences & Experimental Therapeutics, University of Iowa, Iowa City.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Siba</LastName>
<ForeName>Peter M</ForeName>
<Initials>PM</Initials>
<AffiliationInfo><Affiliation>Papua New Guinea Institute of Medical Research, Papua New Guinea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Weil</LastName>
<ForeName>Gary J</ForeName>
<Initials>GJ</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, Infectious Diseases Division, Washington University School of Medicine, St. Louis, Missouri.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kazura</LastName>
<ForeName>James W</ForeName>
<Initials>JW</Initials>
<AffiliationInfo><Affiliation>Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fleckenstein</LastName>
<ForeName>Lawrence L</ForeName>
<Initials>LL</Initials>
<AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences & Experimental Therapeutics, University of Iowa, Iowa City.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>King</LastName>
<ForeName>Christopher L</ForeName>
<Initials>CL</Initials>
<AffiliationInfo><Affiliation>Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Veterans Affairs Medical Center, Cleveland, Ohio.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList><AccessionNumber>NCT01975441</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>10</Month>
<Day>20</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Clin Infect Dis</MedlineTA>
<NlmUniqueID>9203213</NlmUniqueID>
<ISSNLinking>1058-4838</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005369">Filaricides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>70288-86-7</RegistryNumber>
<NameOfSubstance UI="D007559">Ivermectin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>F4216019LN</RegistryNumber>
<NameOfSubstance UI="D015766">Albendazole</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>V867Q8X3ZD</RegistryNumber>
<NameOfSubstance UI="D004049">Diethylcarbamazine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015766" MajorTopicYN="N">Albendazole</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004049" MajorTopicYN="N">Diethylcarbamazine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005369" MajorTopicYN="N">Filaricides</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007559" MajorTopicYN="N">Ivermectin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010219" MajorTopicYN="N">Papua New Guinea</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018512" MajorTopicYN="N">Parasitemia</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D044967" MajorTopicYN="N">Serum</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014958" MajorTopicYN="N">Wuchereria bancrofti</DescriptorName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">albendazole</Keyword>
<Keyword MajorTopicYN="N">chemotherapy</Keyword>
<Keyword MajorTopicYN="N">diethylcarbamazine</Keyword>
<Keyword MajorTopicYN="N">ivermectin</Keyword>
<Keyword MajorTopicYN="N">lymphatic filariasis</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>06</Month>
<Day>20</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>10</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>10</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>10</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>10</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26486704</ArticleId>
<ArticleId IdType="pii">civ882</ArticleId>
<ArticleId IdType="doi">10.1093/cid/civ882</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B76 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000B76 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:26486704
   |texte=   Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:26486704" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.

Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki